EGFR and non-small cell lung carcinoma: Recently, comprehensive genomic profiling by NGS was performed in a subset of patients (n = 51) in order to investigate therapeutic outcomes of NSCLC patients harboring uncommon EGFR mutations other than exon 20 insertions (20ins) and T790M who received first-line therapy of gefitinib/erlotinib/icotinib and afatinib.